UNLIMITED TURBO SHORT - NOVO-NORDISK B | Real-time Euronext Paris 07:48:14 2024-05-24 EDT | ||
| 2.43 EUR | +7.52% |
|
| Current month | -21.93% | ||
| 1 month | -24.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 2.43 | +7.52% |
| 24-05-23 | 2.26 | -9.24% |
| 24-05-22 | 2.49 | +2.05% |
| 24-05-21 | 2.44 | -13.78% |
| 24-05-17 | 2.83 | +7.60% |
Real-time Euronext Paris
Last update May 24, 2024 at 07:48 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| A43NB | |
| ISIN | NLBNPNL2NFR6 |
| Date issued | 2024-02-09 |
| Strike | 1,091 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.08 € |
|---|---|
| Lowest since issue | 2.25 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
937.4
DKK
Average target price
909.2
DKK
Spread / Average Target
-3.00%
- Stock Market
- Certificates
- A43NB Certificat
